Abeona Therapeutics is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

TypePublic
HQDallas, US
Founded2013
Size (employees)19 (est)+217%
Websiteabeonatherapeutics.com
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Abeona Therapeutics

Carsten Thiel

Carsten Thiel

CEO
Timothy J. Miller

Timothy J. Miller

President & Chief Scientific Officer
Jeffrey B. Davis

Jeffrey B. Davis

COO
Juan Ruiz

Juan Ruiz

Chief Medical Officer
Stephen B. Thompson

Stephen B. Thompson

Chief Accounting Officer
Kaye Spratt

Kaye Spratt

Senior Vice President, Regulatory Affairs
Show more

Abeona Therapeutics Office Locations

Abeona Therapeutics has an office in Dallas
Dallas, US (HQ)
600 3333 Lee Pkwy
Show all (1)
Report incorrect company information

Abeona Therapeutics Financials and Metrics

Abeona Therapeutics Revenue

Abeona Therapeutics's revenue was reported to be $837 k in FY, 2017
USD

Revenue (Q3, 2018)

1.7m

Net income (Q3, 2018)

(16.4m)

EBIT (Q3, 2018)

(16.9m)

Market capitalization (17-Dec-2018)

350.5m

Closing stock price (17-Dec-2018)

7.3

Cash (30-Sep-2018)

33.6m
Abeona Therapeutics's current market capitalization is $350.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.0m925.0k1.0m889.0k837.0k

Revenue growth, %

(55%)12%(15%)

General and administrative expense

4.8m14.3m13.3m10.9m

R&D expense

884.0k4.7m10.7m17.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

189.0k208.0k247.0k236.0k258.0k282.0k285.0k235.0k214.0k184.0k186.0k217.0k219.0k2.6m819.0k1.7m

General and administrative expense

642.0k733.0k868.0k795.0k1.7m3.7m4.7m4.4m3.7m2.4m3.0m2.6m2.2m2.9m4.6m5.0m

R&D expense

236.0k72.0k81.0k73.0k453.0k610.0k1.6m1.9m3.0m2.7m2.2m5.8m3.3m8.2m7.9m13.2m

Operating expense total

885.0k805.0k950.0k869.0k2.3m4.4m6.4m6.4m6.9m5.4m5.5m8.7m5.6m11.2m12.8m18.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

424.0k11.5m40.1m69.1m137.8m

Accounts Receivable

74.0k115.0k107.0k

Inventories

77.0k315.0k155.0k

Current Assets

575.0k11.6m40.6m69.4m140.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

899.0k299.0k55.0k165.0k7.9m30.4m43.3m37.4m34.3m31.2m63.2m58.3m56.5m132.0m50.0m33.6m

Accounts Receivable

56.0k59.0k58.0k3.0k330.0k271.0k244.0k112.0k606.0k148.0k97.0k111.0k64.0k47.0k352.0k

Inventories

1.8m

Current Assets

1.0m440.0k203.0k244.0k8.2m31.0m43.7m37.8m34.6m31.9m63.8m59.3m58.4m134.2m121.8m114.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

4.4m(26.8m)(14.5m)(21.9m)(27.3m)

Depreciation and Amortization

3.0k11.0k551.0k825.0k741.0k

Inventories

194.0k77.0k(287.0k)160.0k

Accounts Payable

(1.2m)33.0k(1.2m)2.8m(1.3m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

5.5m(128.0k)(13.4m)(14.8m)(2.0m)(6.1m)(12.2m)(5.5m)(12.2m)(14.9m)(5.2m)(13.5m)(18.9m)(8.5m)(20.2m)(36.6m)

Depreciation and Amortization

2.0k1.0k2.0k118.0k250.0k401.0k174.0k355.0k577.0k250.0k457.0k595.0k174.0k464.0k969.0k

Inventories

194.0k

Accounts Payable

(1.3m)212.0k477.0k767.0k638.0k(731.0k)(1.1m)167.0k1.2m1.0m(2.2m)(77.0k)(1.7m)3.5m3.4m7.9m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Abeona Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Abeona Therapeutics News and Updates

Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day

EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment

Abeona Therapeutics to Host R&D Day on December 6, 2018

NEW YORK and CLEVELAND, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced it will host its 2nd R&D Day eve…

Abeona Therapeutics Announces CEO Transition

Dr. Carsten Thiel to Depart Company Immediately; Dr. João Siffert Appointed Interim CEO Dr. Carsten Thiel to Depart Company Immediately; Dr. João Siffert Appointed Interim CEO

Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights

NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the third quar…

Alpha-1 Antitrypsin Drugs Global Market 2018 Top Key Players – Baxter , CSL Behring, Grifols, Kamada, Abeona Therapeutics , Alnylam Pharmaceuticals , Applied Genetic, Technologies and Forecast to 2023

Wiseguyreports.Com Added New Market Research Report On -“Alpha-1 Antitrypsin Drugs Market 2018 Key Players, Applications and Future Demand Forecast to 2023 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer

NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Siffert, M.D…
Show more
Report incorrect company information

Abeona Therapeutics Blogs

Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference

NEW YORK and CLEVELAND, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that management will participate in…

Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10 million paid upon signing, $10 million by first anniversary of agreement; annual payments of $20 mi…

Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain

Clinical trial for ABO-101 (AAV-NAGLU) marks the 2nd MPS III program in Europe Company plans to initiate additional clinical sites in European countries including France, Germany and the United Kingdom NEW YORK and CLEVELAND, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:…

Abeona Announces Participation at Upcoming Conferences

Citi's 13th Annual Biotech Conference - September 5-6th in Boston, MA Jefferies Gene Therapy Summit - September 27th in New York, NY NEW YORK and CLEVELAND, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on…

Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer

NEW YORK and CLEVELAND, July 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Max Colao as Chie…

Abeona Therapeutics Company Life and Culture

Report incorrect company information

Abeona Therapeutics Frequently Asked Questions

  • When was Abeona Therapeutics founded?

    Abeona Therapeutics was founded in 2013.

  • Who are Abeona Therapeutics key executives?

    Abeona Therapeutics's key executives are Carsten Thiel, Timothy J. Miller and Jeffrey B. Davis.

  • How many employees does Abeona Therapeutics have?

    Abeona Therapeutics has 19 employees.

  • What is Abeona Therapeutics revenue?

    Latest Abeona Therapeutics annual revenue is $837 k.

  • What is Abeona Therapeutics revenue per employee?

    Latest Abeona Therapeutics revenue per employee is $44.1 k.

  • Who are Abeona Therapeutics competitors?

    Competitors of Abeona Therapeutics include GenVec, miRagen Therapeutics and Solid BioSciences.

  • Where is Abeona Therapeutics headquarters?

    Abeona Therapeutics headquarters is located at 600 3333 Lee Pkwy, Dallas.

  • Where are Abeona Therapeutics offices?

    Abeona Therapeutics has an office in Dallas.

  • How many offices does Abeona Therapeutics have?

    Abeona Therapeutics has 1 office.